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What is New in Version 2
The following features are new for Version 2 of the Cost Calculator:
 Inclusion of asthma, arthritis and depression
 Estimates of the medical costs of the selected chronic diseases to Medicare, private 
insurance, and all payers combined (including other payers such as TRICARE, out-of-
pocket, the uninsured, etc.)
 Estimates of absenteeism costs for the selected chronic diseases at the state level
 Projections of estimates of the medical costs of selected chronic diseases through 2020.
Default Source Data Sets
Enrollment 
U.S. Census Bureau
Total state population and breakdowns by sex and age for 2008 and state population 
projections by sex and age for 2010 through 2020 came from the U.S. Census Bureau.
1,2 
Kaiser Family Foundation
Medicare beneficiary data came from the Kaiser Family Foundation 2008 Medicare 
Health and Prescription Drug Plan Tracker.
3 
Medicaid Statistical Information System (MSIS)
Medicaid enrollment data came from the Medicaid Statistical Information System (MSIS)
State Summary Fiscal Year 2008.
4 
MSIS data are used by CMS to produce Medicaid program
characteristics and utilization information for the states. The purpose of MSIS is to collect, 
manage, analyze and disseminate information on eligibles, beneficiaries, utilization and payment
for services covered by State Medicaid programs. 
Current Population Survey (CPS)
Private insurance enrollment data and breakdowns of enrollment by sex and age by payer 
(private insurance, Medicaid, and Medicare) came from the Current Population Survey (CPS).
5 
Private insurance data came from the 2008 CPS and Medicaid and Medicare data came from the
2007 through 2009 CPS. The Current Population Survey (CPS) is a monthly survey of about 
50,000 households conducted by the Bureau of the Census for the Bureau of Labor Statistics. 
The sample is scientifically selected to represent the civilian noninstitutional population. The 
sample provides estimates for the nation as a whole and serves as part of model-based estimates 













   
  
 
   





















    
   
Treated Population, Per-Person Costs, and Absenteeism
(Treated population is defined as the number of people receiving care for the disease in the 
previous year.)
Medical Expenditure Panel Survey (MEPS)
Data were pooled from the 2004 through 2008 Medical Expenditure Panel Survey 
(MEPS) Consolidated Data Files, a nationally representative survey of the civilian non-
institutionalized population that provides data on annual medical expenditures, sources of 
payment, insurance coverage, and days missed from work due to illness or injury for each 
participant.
6 
Diseases were defined using ICD-9 codes based on self-reported diseases that were
transcribed by professional coders and reported in the MEPS Medical Conditions files for years 
2004 through 2008 (see Appendix). 
The combined five-year MEPS sample included 153,012 persons of all ages living in the
U.S. Estimates for both the treated population and costs have been adjusted to be nationally 
representative using MEPS sampling weights for years 2004 through 2008. The default data 
include years prior to the implementation of Medicare Part D, which took effect in 2006. All 
expenditure data were inflated to 2010 dollars using the gross domestic product general price 
index as recommended by AHRQ to reflect more current dollar values.
7 
National Nursing Home Survey (NNHS)
Estimates for the institutionalized population, which are not available in other data 
sources, were derived from the 2004 National Nursing Home Survey (NNHS). The NNHS is a
nationally representative sample of United States nursing homes, their services, their staff, and 
their residents.
78 
The NNHS provides information on nursing homes from two perspectives- -
that of the provider of services and that of the recipient of care. For recipients, data were 
obtained on demographic characteristics, health status, and sources of payment. Diseases were 
defined using ICD-9 codes based on any diagnosis of the condition, either at admission or time 
of the survey and primary or secondary diagnosis (see Appendix). 
Methodology
This section describes the methods used to generate the default values in the Cost 
Calculator. We estimated the treated population and per-person medical and absenteeism costs 
by sex by age (e.g., males age 65+) using complex survey weights in MEPS and NNHS. 
However, small sample sizes in MEPS preclude reporting of treated population and costs by sex 
by age subgroups. Where sample sizes permit, we report treated population and costs separately 
by sex and by age group. We do this by calculating weighted averages of the estimates by sex by 
age, where the weights are derived from the payer population distribution in each state. Thus, we 
apply nationally-representative treated population and per-person medical and absenteeism costs 
by sex by age to states using state-level demographics. This assures that the subgroup and total 
population percent treated and costs will always be consistent with one another for any payer
population the user enters (i.e., the sum of payer disease costs by sex and the sum of payer














   






   
 
 
    
  
    
  
 
   
  






   
 
   
Enrollment 
Payer enrollment was taken from the following sources: all payers combined from U.S. 
Census Bureau estimates for 2008, Medicaid from MSIS State Summary Fiscal Year 2008, 
Medicare from the Kaiser Family Foundation 2008 Medicare Health and Prescription Drug Plan 
Tracker, and private insurance from the 2008 CPS. Total state population for 2008 was used for 
all payers combined. Beneficiaries who were only enrolled in capitated Medicaid managed care 
during the year were included in the Medicaid population. Medicare population included 
individuals with Medicare Parts A and/or B.
CMS does not report Medicaid or Medicare enrollment by sex by age. For each payer, we 
estimated the distribution of the population by sex by age using the CPS (2008 for private 
insurance and 2007 through 2009 for Medicaid and Medicare). We then applied these 
distributions to each of the state enrollment populations. The resulting payer population 
distributions by sex by age were used as weights to calculate weighted average percent treated 
and per-person medical and absenteeism costs by sex, by age, and for the overall payer 
population in each state.
Treated Population  
Treated population is defined as the number of people receiving care for the disease in
the previous year.
 The MEPS 2004-2008 Condition files were used to define treated population. We 
restricted our condition indicators to those for which respondents received care within
the interview year.
 Treated population in the MEPS data was based on self-reports of receiving care for the 
disease within the interview year.
o	 For example, a person in remission for cancer but who visited a doctor for a
follow-up appointment during the interview year would be included in the cancer 
treated population. A person with a history of hypertension but who did not have 
any medical treatment (appointments or medication) during the interview year
would not be included in the hypertension treated population.
o	 Persons identified as having the disease in the MEPS thus are likely more 
resource-intensive (higher cost) than those included in alternative prevalence 
definitions based on a lifetime history of the disease.
 Treated populations were estimated by payer/sex/age subgroups at the Census region
level, the most detailed geographic data available in the public use MEPS. Because 
sample sizes were often small at the payer/sex/age/region level, we used logistic 
regression analysis to smooth the percent treated estimates. 
o	 For each payer and disease, we used logistic regression to predict the percent
treated as a function of sex, age, and region. Stepwise regression was used to test 
for the presence of statistically significant interactions of age, sex, and region for 













   



























regression specification that was used to predict the percent treated by age, sex, 
and region.
o	 Where the relative standard error of predicted percent treated was greater than 
30% for sex or age breakdowns at the region level, the Cost Calculator does not 
report output by these subgroups.
 All default percent treated estimates were weighted using the MEPS sampling weights to 
be nationally representative. Nationally-representative estimates by payer/sex/age were 
then applied to state-level population data (see p. 4). 
 Treated populations in the MEPS data did not include those in long-term care (LTC) 
facilities since the target population for the MEPS is the civilian non-institutionalized 
population.  Therefore, all MEPS percent treated estimates were scaled to account for 
non-coverage of the LTC population. The scaling factor, calculated by combining percent
treated estimates in MEPS and NNHS, was the ratio of overall percent treated including 
the LTC population to percent treated in the non-LTC population. Separate ratios were 
used for each payer/sex/age subpopulation. However, because NNHS did not include
regional identifiers, scaling factors at the national level were used for each of the Census 
regions in MEPS.  
 Children (i.e., ages 0 to 17) were assumed to have zero percent treated for all diseases 
except asthma and depression. The small number of children with the other diseases in 
MEPS prevented reliable estimates for this age group. As a check of this assumption, in 
separate analyses we conducted using Medicaid claims data from Illinois, Indiana, 
Kansas and Louisiana (unpublished), which had sufficient number of children with the
diseases reported in the Cost Calculator, percent treated estimates for children were very 
small: heart disease = 0.25%, congestive heart failure (CHF) = 0.03%, hypertension = 
1.5%, stroke = 0.04%, diabetes = 0.20%, and cancer = 0.12%.
Per-Person Medical Costs
Regression modeling was used to estimate the costs associated with selected chronic 
diseases. The regression approach isolated the impact of diseases on health care costs while 
controlling for the presence of other important drivers of medical expenditures. Models were run 
for each payer population. Sample sizes were too small to estimate separate models by sex by
age. Results reported by sex and by age category were generated from weighted averages of 
simulations by sex by age using the regression model for the entire payer population (see below 
for description of simulations). Nonlinearities in the overall model will generate different
average costs per person for the different sex/age groups. 
 A two-part regression model was used to predict annual per-person costs. The first part of 
the two-part model used logistic regression to predict the probability of any expenditure. 
The second part of the two-part model analyzed expenditures conditional on having any 
expenditures (i.e., any utilization that generated expenditures >0). To select the
appropriate cost estimation model for the second part of the two-part model, we used the
algorithm for choosing among alternative non-linear estimators recommended by 
Manning and Mullahy.
9 
The results of this algorithm indicated that we should use a 
generalized linear model (GLM) with a gamma distribution and a log link in the second 








    
  
   
 












   
 












     









 The dependent variable in each regression was restricted to the annual medical 

expenditures paid by each payer. 

 All regressions included the following variables: indicators for arthritis, asthma, cancer, 
congestive heart failure (CHF), coronary heart disease (CHD), hypertension, stroke, other
heart diseases,
† 
depression, and diabetes; age; age squared; sex; race/ethnicity; education; 
family income; other sources of health insurance; year indicators; and indicators for other 
diseases including injuries, dyslipidemia, HIV/AIDS, pneumonia, chronic obstructive
pulmonary disease, other mental health/substance abuse, back problems, skin disorders, 
renal failure, and pregnancies. 
 Hypertension and diabetes are risk factors for other diseases included in the cost 
estimation model; therefore, the full model likely underestimated the true costs of 
hypertension and diabetes. To capture the costs of diseases on the causal pathway, the 
estimates for hypertension and diabetes are from alternate models we created that omitted 
controlling for diseases linked to hypertension and diabetes. 
o	 The hypertension model dropped CHF, CHD, other heart diseases, renal failure, 
and stroke. 
o	 The diabetes model dropped CHF, CHD, other heart diseases, hypertension, renal
failure, stroke and dyslipidemia. 
 Relative standard errors for the national MEPS Medicaid disease expenditures, the 
smallest sample among payers in the analysis, range from 21% to 35% across diseases.
 Confidential MEPS data that identified the largest 30 states and 9 census divisions were
utilized to generate state-specific per-person cost estimates.
o	 Payer sample sizes were not large enough by state to replicate the full analysis for 
each state. 
o	 We regressed log (positive) medical expenditures on the variables in the model 
plus state/census division dummies. 
o	 The coefficients on the dummies provided measures of the differences in average 
medical costs across states that were used to scale the national estimates to make 
them state-specific.
 The MEPS does not include expenditures associated with persons residing in institutions.
The following steps were taken to include LTC costs in the per-person cost estimates: 
o	 We used a “top-down” approach to generate disease-specific LTC costs for all 
payers combined, Medicaid, and Medicare. Private insurance is not a major payer
for LTC so these costs were not estimated for private insurers. All of the steps that
follow were performed separately for each payer. 
o	 There are no nationally-representative data sets that include both diagnoses and 
medical expenditures for the LTC population. Therefore, we assumed that LTC
costs are proportional to length of stay, which is available in the NNHS. The 
assumption was that the LTC costs are based on per diem payments and are 
constant across diseases except for length of stay. Acute treatment for specific 
conditions is often charged to physicians or other settings, which will be captured 
in the non-LTC cost category.
† Other heart diseases includes rheumatic fever/rheumatic heart disease, diseases of mitral and aortic valves and 
other endocardial structures, acute and chronic pulmonary heart disease, acute and other pericardial and endocardial 
disease, cardiomyopathy, conduction disorders, cardiac dysrhythmias and ill-defined heart disease. See Appendix 









   
   
  
   
 
   
   
  
 

















    
  
   
  
   
   
 
o	 From the 2004 NNHS, we calculated the total number of days for patients with a
primary diagnosis of each disease at admission using the date of admission. 
o	 Next, we calculated the percentage of all nursing home days accounted for by 
each primary diagnosis. The use of primary diagnosis assumed that length of stay 
(and LTC expenditure) was not compounded by the presence of other diseases.
o	 Then we multiplied the percentage of all nursing home days for each primary 
diagnosis (disease) by national health accounts total nursing home expenditures to 
get disease-specific total nursing home expenditures.
10 
o	 Next, we divided disease-specific nursing home expenditures by the total number
of people with the disease (LTC from NNHS and the non-LTC, non-
institutionalized population from MEPS). 
o	 Finally, we added the above to the MEPS per-person cost for each disease. The
national LTC per-person cost estimate was added to the MEPS estimates before 
converting to state-level estimates using the state/census division multipliers.
 Costs per person attributable to each disease were calculated using the following method 
that minimizes double-counting of expenditures across diseases.
11 
o	 First, every unique combination of the chronic diseases observed in the data was 
identified (e.g., stroke, stroke with hypertension, and stroke with CHF are three of 
the unique combinations). 
o	 Second, expenditures were predicted for each individual.
o	 Then, for each unique combination of diseases, we subtracted from step two the
predicted expenditures for an otherwise identical person without the combination 
of diseases. This provides an estimate of the costs attributable to every unique
combination of diseases. 
o	 Next, the coefficients of the diseases from the second part of the two part 
regression model were used as importance weights to redistribute costs associated 
with jointly-occurring diseases to constituent diseases (e.g., to redistribute the
costs of stroke with hypertension back to stroke and hypertension separately). 
o	 Finally, the application averages the redistributed costs over the population with 
each disease.
o	 There should not be any double-counting of costs between the LTC and non-LTC
analyses because the former only includes the LTC component of costs, which are 
excluded entirely from the non-LTC analyses.
Per-Person Absenteeism Costs 
Regression modeling was used to estimate absenteeism costs associated with selected 
chronic diseases. Please note that other indirect costs of chronic disease, including productivity 
losses through presenteeism and premature mortality and reductions in the quality of life, are not
included in the estimates. The model for work days missed was estimated for the adult working 
population from MEPS. Sample sizes were too small to estimate separate models by sex by age.
Results reported by sex and by age category were generated from weighted averages of 
simulations by sex by age using the regression model for the entire working population (see 
below for description of simulations). The nonlinear regression model will generate different











    
  


























   
 
  
 A negative binomial model was used to predict annual work days missed per working 
person. Negative binomial models, an extension of Poisson models, are used when the 
dependent variable is a count (i.e., a non-negative integer).
 The dependent variable was annual work days missed due to illness or injury. 
 All regressions included the following variables: indicators for arthritis, asthma, cancer, 
CHF, CHD, hypertension, stroke, other heart diseases, depression, and diabetes; age; age 
squared; sex; race/ethnicity; education; family income; sources of health insurance; 
family size; occupation; year indicators; and indicators for other diseases including
injuries, dyslipidemia, HIV/AIDS, pneumonia, chronic obstructive pulmonary disease, 
other mental health/substance abuse, back problems, skin disorders, renal failure, and 
pregnancies.
 Hypertension and diabetes are risk factors for other diseases included in the absenteeism
estimation model; therefore, the full model likely underestimated the true absenteeism
costs of hypertension and diabetes. To capture the absenteeism costs of diseases on the 
causal pathway, the estimates for hypertension and diabetes are from alternate models we 
created that omitted controlling for diseases linked to hypertension and diabetes. 
o	 The hypertension model dropped CHF, CHD, other heart diseases, renal failure, 
and stroke. 
o	 The diabetes model dropped CHF, CHD, other heart diseases, hypertension, renal
failure, stroke and dyslipidemia. 
 Because asthma and depression are prevalent among children, we also estimated negative 
binomial models for the annual number of school days missed due to illness or injury
using the full specification above. We assumed that working parents must also miss work 
on the days that their children miss school. 
 Work days missed per person attributable to each disease was calculated using the same 
method as above for medical cost, which minimizes double-counting across diseases.
11 
Calculated Costs
 The total payer population with a disease is calculated by multiplying the payer
 
population by the percent treated. 

 The total annual payer costs attributable to a disease are calculated by multiplying the 
average annual costs per person with the disease by the payer population with the disease.
 The total payer costs for all selected diseases are calculated by summing the total annual 
payer costs attributable to each disease. However, as described above, the cost estimates 
for hypertension and diabetes include the costs of complications such as CHD, CHF, 
stroke, and other heart diseases. The sum of costs over selected diseases that include
hypertension and diabetes could overestimate the costs associated with all the selected 
diseases. The Cost Calculator provides estimates for “Diseases of the Heart” and “Total
CVD” that avoid double-counting of costs across diseases. The costs for “Diseases of the 
Heart” include CHD, CHF, and other heart disease. The costs for “Total CVD” include 
“Diseases of the Heart,” stroke, and an estimate of hypertension costs that avoids double-
counting of costs with other diseases. Excluding the costs of complications lowers the 
estimates for hypertension and diabetes by approximately 34% and 39%, respectively.
 The total absenteeism costs attributable to a disease are calculated by multiplying the 








    







       




    
      
 
     
   













for the disease that are employed, the average annual work days missed per person due to 
the disease, and average daily earnings. 
o	 The percentage of people treated for the disease that are employed was taken from
MEPS. For children with asthma and/or depression, we used the percentage of
children whose parents work full time.
o	 Average daily earnings were taken from the 2009 CPS. The earnings were not 
disease specific.
12 
We used average daily earnings for females ages 18 to 44 to 
proxy for parents of young children with asthma and/or depression.
Medical Cost Projections
We generated projections of the medical cost of the chronic diseases to all payers 
combined through 2020 using default input data from MEPS and the U.S. Census Bureau. The 
medical cost projections include nursing home costs but exclude absenteeism costs. The 
projections are reported in real 2010 dollars and do not project inflation. The projections 
assume no changes in policy or technology and exclude changes due to the Affordable Care 
Act (PL 111-148). All the changes in the real medical cost of disease are driven by growth in 
13-15 
real medical costs and change in the treated population, which is in turn driven by changes in 
population size and age and gender distributions. 
 We obtained projections of population counts by sex by age for each state through 2020 
from the Census.
 We then applied the percent treated for each disease by sex by age from MEPS to the
Census population counts by sex by age and by state through 2020 to obtain projections 
of the number of people with each disease by sex by age by state.
 Next, we multiplied the number of people with each disease by sex/age/state by the state-
specific per-person medical cost estimate by sex by age (see above).
 We used Congressional Budget Office assumptions for future health care cost growth 
14-15 
above and beyond growth due to population growth and aging. We assumed that per-
person costs will increase at the same rate as overall medical expenditures between 2010 
and 2020: an average annual rate of 3.6%.  
 Finally, we aggregated cost estimates across sex and age cells for each state to obtain
total medical cost projections for each disease by state through 2020.
External Review
The methods used in generating estimates for the Cost Calculator were reviewed by an 
external panel of subject matter experts in the autumn of 2010. Comments from Drs. Steven 

















































Absenteeism: Absence from work. The Cost Calculator’s primary measure of lost productivity
is absence from work due to chronic disease.
Attributable: The portion of expenditures directly associated with a disease. 
BRFSS: Behavioral Risk Factor Surveillance System
CHD: Coronary heart disease 
CHF: Congestive heart failure
CMS: Centers for Medicare & Medicaid Services
CPS: Current Population Survey
CVD: Cardiovascular disease 
Generalized linear model: A type of non-linear estimation used to compute the relationship 
between a set of independent variables and a dependent variable that has a non-normal
distribution. In this case, the independent variables are the demographics and the disease
indicators and the dependent variable is strictly positive payer expenditures, which is positively 
skewed.
ICD-9: International Classification of Diseases, Ninth Revision
Logistic regression: A type of non-linear estimation used to compute the relationship between a 
set of independent variables and a discrete dependent variable.  In this case, the independent
variables are the demographics and the disease indicators and the dependent variable is the 
probability of having positive payer expenditures. 
LTC: Long-term care
MEPS: Medical Expenditure Panel Survey
MSIS: Medicaid Statistical Information System 
Negative binomial model: A type of non-linear estimation used to compute the relationship 
between a set of independent variables and a count dependent variable (i.e., a dependent variable 
that takes on non-negative integer values).  In this case, the independent variables are the 
demographics and the disease indicators and the dependent variable is the annual number of 
work days missed due to illness or injury.




      
   
   
 
   
 
Per-person costs: Average payer costs per person with the disease attributable to the disease.  
These numbers represent the extent to which payer expenditures per person with the disease 
would be lower in the absence of the disease, all else constant.
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Table 1: Chronic Disease Definitions—Clinical Classification (CC) Code* and 3-digit ICD-
9 
 
Arthritis ICD-9: 274, 354, 390, 391, 443, 446, 710-716, 
719-721, 725-729 
Asthma CC: 128 ICD-9: 493
Cancer CC: 11-43, 45
Cardiovascular Disease (CVD)
Congestive heart failure ICD-9: 428
Coronary heart disease ICD-9: 410-414
Hypertension ICD-9: 401-405
Stroke ICD-9: 430-434, 436-438
Other heart diseases ICD-9: 390-392, 393-398, 415-416, 420-427, 
429
Depression ICD-9: 296, 311
Diabetes ICD-9: 250
*http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.  
 
 
